Journal of Pediatric Hematology/Oncology · 1993 · 33 citations · 0 references
EducationHuman DevelopmentPediatricsChild DevelopmentDevelopmental PediatricsDiagnostic AssessmentDevelopmental AssessmentDevelopmental DisordersDevelopmental NeuropsychologyNeurodevelopmental AssessmentPediatric NeuropsychologySickle Cell DiseaseDenver Developmental Screening TestDevelopmental ScreeningDevelopmental Screening Tools ValidationNeuropsychological FunctioningNeuropsychological ImpairmentScreening Test InterpretationScreening Test ValiditySickle Cell Anemia
PURPOSE: The goal of the study was to assess development in young children with sickle cell disease as part of the Cooperative Study of Sickle Cell Disease (CSSCD). PATIENTS AND METHODS: The Denver Developmental Screening Test (DDST) was administered to children younger than 6 years at 12 participating institutions of the CSSCD. Trained examiners administered tests to 344 children. RESULTS: Tests were scored as normal in 90.4%, questionable in 6.4%, and abnormal in 1.5%; 1.7% of children were considered untestable. There was no relationship between DDST results and sickle cell genotype. Questionable and abnormal (Q/A) scores were more common in children ages 3-5 years than in younger children (12.6% versus 3.8%; P = 0.002). CONCLUSIONS: Because the DDST is a screening test, it should be interpreted cautiously. However, the more numerous Q/A scores in our "older" group agree with the findings of recent reports of neuropsychological impairment in school-age children with sickle cell disease. Our data suggest that development is relatively normal before age 3 years; deficits seen in older children may reflect subsequent ischemic insults.